GSK461364

Contact us
TargetMol
Product Code: TAR-T6282
Supplier: TargetMol
CodeSizePrice
TAR-T6282-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-5mg5mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-1mL1 mL * 10 mM (in DMSO)£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-10mg10mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-25mg25mg£245.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-50mg50mg£386.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-100mg100mg£542.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-200mg200mg£744.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6282-500mg500mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1
❮❯

Documents

Further Information

Bioactivity:
GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
CAS:
929095-18-1
Formula:
C27H28F3N5O2S
Molecular Weight:
543.61
Pathway:
Cell Cycle/Checkpoint
Purity:
0.995
SMILES:
C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F
Target:
PLK

References

Yu Z, Deng P, Chen Y, et al. Inhibition of the PLK1?Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. Advanced Science. 2021: 2100759. Degenhardt Y, et al. Mol Cancer Ther, 2010, 9(7), 2079-2089. Gilmartin AG, et al. Cancer Res, 2009, 69(17), 6969-6977. Yu Z, Deng P, Chen Y, et al. Inhibition of the PLK1?Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. Advanced Science. 2021: 2100759. Olmos D, et al. Clin Cancer Res, 2011, 17(10), 3420-3430.